155 related articles for article (PubMed ID: 38290769)
1. Combination of oligo-fractionated irradiation with nivolumab can induce immune modulation in gastric cancer.
Mimura K; Ogata T; Nguyen PHD; Roy S; Kared H; Yuan YC; Fehlings M; Yoshimoto Y; Yoshida D; Nakajima S; Sato H; Machida N; Yamada T; Watanabe Y; Tamaki T; Fujikawa H; Inokuchi Y; Hayase S; Hanayama H; Saze Z; Katoh H; Takahashi F; Oshima T; Goel A; Nardin A; Suzuki Y; Kono K
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290769
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer.
Mimura K; Ogata T; Yoshimoto Y; Yoshida D; Nakajima S; Sato H; Machida N; Yamada T; Watanabe Y; Tamaki T; Fujikawa H; Inokuchi Y; Hayase S; Hanayama H; Saze Z; Katoh H; Takahashi F; Oshima T; Suzuki Y; Kono K
Commun Med (Lond); 2023 Aug; 3(1):111. PubMed ID: 37582945
[TBL] [Abstract][Full Text] [Related]
3. The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer.
Nose Y; Saito T; Yamamoto K; Yamashita K; Tanaka K; Yamamoto K; Makino T; Takahashi T; Kawashima A; Haruna M; Hirata M; Ueyama A; Iwahori K; Satoh T; Kurokawa Y; Eguchi H; Doki Y; Wada H
Cancer Immunol Immunother; 2023 Jan; 72(1):169-181. PubMed ID: 35776160
[TBL] [Abstract][Full Text] [Related]
4. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
5. CD45RA
Kunert A; Basak EA; Hurkmans DP; Balcioglu HE; Klaver Y; van Brakel M; Oostvogels AAM; Lamers CHJ; Bins S; Koolen SLW; van der Veldt AAM; Sleijfer S; Mathijssen RHJ; Aerts JGJV; Debets R
J Immunother Cancer; 2019 Jun; 7(1):149. PubMed ID: 31176366
[TBL] [Abstract][Full Text] [Related]
6. Tumor mutational load, CD8
Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
[TBL] [Abstract][Full Text] [Related]
7. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
[TBL] [Abstract][Full Text] [Related]
8. Characterization of tumoricidal activities mediated by a novel immune cell regimen composing interferon-producing killer dendritic cells and tumor-specific cytotoxic T lymphocytes.
Fang CH; Cheng WF; Cheng YF; Lan KL; Lee JM
BMC Cancer; 2024 Mar; 24(1):395. PubMed ID: 38549061
[TBL] [Abstract][Full Text] [Related]
9. Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma.
Dave H; Terpilowski M; Mai M; Toner K; Grant M; Stanojevic M; Lazarski C; Shibli A; Bien SA; Maglo P; Hoq F; Schore R; Glenn M; Hu B; Hanley PJ; Ambinder R; Bollard CM
Blood Adv; 2022 Jan; 6(2):473-485. PubMed ID: 34495306
[TBL] [Abstract][Full Text] [Related]
10. Effector CD8+CD45RO-CD27-T cells have signalling defects in patients with squamous cell carcinoma of the head and neck.
Kuss I; Donnenberg AD; Gooding W; Whiteside TL
Br J Cancer; 2003 Jan; 88(2):223-30. PubMed ID: 12610507
[TBL] [Abstract][Full Text] [Related]
11. Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients.
Capone M; Fratangelo F; Giannarelli D; Sorrentino C; Turiello R; Zanotta S; Galati D; Madonna G; Tuffanelli M; Scarpato L; Grimaldi AM; Esposito A; Azzaro R; Pinto A; Cavalcanti E; Pinto A; Morello S; Ascierto PA
J Transl Med; 2020 Mar; 18(1):121. PubMed ID: 32160899
[TBL] [Abstract][Full Text] [Related]
12. Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer.
Lheureux S; Matei DE; Konstantinopoulos PA; Wang BX; Gadalla R; Block MS; Jewell A; Gaillard SL; McHale M; McCourt C; Temkin S; Girda E; Backes FJ; Werner TL; Duska L; Kehoe S; Colombo I; Wang L; Li X; Wildman R; Soleimani S; Lien S; Wright J; Pugh T; Ohashi PS; Brooks DG; Fleming GF
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288469
[TBL] [Abstract][Full Text] [Related]
13. VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial.
Coffman-D'Annibale K; Myojin Y; Monge C; Xie C; Hrones DM; Wood BJ; Levy EB; Kleiner D; Figg WD; Steinberg SM; Redd B; Greten TF
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38184304
[TBL] [Abstract][Full Text] [Related]
14. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
[TBL] [Abstract][Full Text] [Related]
15. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal analysis of T-cell receptor repertoires reveals persistence of antigen-driven CD4
Servaas NH; Zaaraoui-Boutahar F; Wichers CGK; Ottria A; Chouri E; Affandi AJ; Silva-Cardoso S; van der Kroef M; Carvalheiro T; van Wijk F; Radstake TRDJ; Andeweg AC; Pandit A
J Autoimmun; 2021 Feb; 117():102574. PubMed ID: 33307312
[TBL] [Abstract][Full Text] [Related]
17. Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma.
Di Blasi D; Boldanova T; Mori L; Terracciano L; Heim MH; De Libero G
Cell Mol Gastroenterol Hepatol; 2020; 9(2):195-218. PubMed ID: 31445190
[TBL] [Abstract][Full Text] [Related]
18. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control.
Rodriguez-Ruiz ME; Serrano-Mendioroz I; Garate-Soraluze E; Sánchez-Mateos P; Barrio-Alonso C; Rodríguez López I; Diaz Pascual V; Arbea Moreno L; Alvarez M; Sanmamed MF; Perez-Gracia JL; Escuin-Ordinas H; Quintero M; Melero I
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36631161
[TBL] [Abstract][Full Text] [Related]
20. ISA101 and nivolumab for HPV-16
Sousa LG; Rajapakshe K; Rodriguez Canales J; Chin RL; Feng L; Wang Q; Barrese TZ; Massarelli E; William W; Johnson FM; Ferrarotto R; Wistuba I; Coarfa C; Lee J; Wang J; Melief CJM; Curran MA; Glisson BS
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
